Lofty expectations for continuing sales of vaccines and antivirals have fallen short, sending Pfizer's stock price tumbling ...

That’s why there’s been so much excitement about a new class of drugs that’s helping patients shed dozens of pounds at far ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on GPCR stock, giving a Buy rating on August 9. David Risinger has ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Skye Bioscience (SKYE – Research Report) ...